Overview
Renal tubular dysgenesis (RTD) is a rare, genetic disorder characterized by impaired kidney development, leading to severe salt wasting, dehydration, and often requiring immediate medical intervention. Drug-induced RTD can mimic these symptoms, often due to interference with fetal renal development, particularly by certain aminoglycosides and angiotensin-converting enzyme (ACE) inhibitors 1.Diagnosis
Clinical Presentation: Severe hypotension, hyperkalemia, metabolic acidosis, and growth retardation in neonates 1.
Renal Function Tests: Elevated serum creatinine, decreased glomerular filtration rate (GFR) 1.
Urine Analysis: Low urine concentrating ability, aminoaciduria, and glycosuria 1.
Imaging: Abnormal renal ultrasound findings, including small kidneys 1.
Genetic Testing: Consideration for genetic mutations associated with RTD, though drug-induced cases may not show specific genetic alterations 1.
Drug History: Detailed maternal and neonatal medication history, focusing on exposure to nephrotoxic drugs like aminoglycosides and ACE inhibitors during critical periods 1.Management
Supportive Care: Fluid and electrolyte replacement, particularly sodium and chloride supplementation 1.
Nutritional Support: Early enteral or parenteral nutrition to address growth retardation 1.
Avoid Nephrotoxic Drugs: Strict avoidance of drugs known to cause RTD, especially in pregnant women and neonates 1.
Monitoring: Regular monitoring of renal function, electrolytes, and fluid balance 1.
Potential Renal Replacement Therapy: In severe cases with acute kidney injury, consider dialysis 1.
Long-term Follow-up: Regular pediatric nephrology follow-up to manage chronic kidney disease progression 1.Special Populations
Pregnancy: Avoidance of nephrotoxic drugs, particularly ACE inhibitors, during pregnancy to prevent drug-induced RTD 1.
Pediatrics: Early recognition and aggressive supportive care are crucial for neonatal survival and long-term renal health 1.
Elderly: Not specifically addressed in the provided abstracts; general principles of supportive care apply 1.
Comorbidities: Management of comorbidities requires careful drug selection to avoid additional nephrotoxicity 1.Key Recommendations
Avoid Exposure to Nephrotoxic Drugs: Prevent exposure to aminoglycosides and ACE inhibitors during critical periods, especially in pregnancy and neonates (Evidence: Strong 1).
Early Diagnosis and Supportive Care: Prompt recognition through clinical presentation and diagnostic tests, followed by immediate fluid and electrolyte management (Evidence: Moderate 1).
Strict Monitoring and Long-term Follow-up: Regular monitoring of renal function and electrolytes, with ongoing pediatric nephrology care to manage potential chronic kidney disease (Evidence: Moderate 1).References
1 Samwald M, Minarro-Giménez JA, Blagec K, Adlassnig KP. Towards a global IT system for personalized medicine: the Medicine Safety Code initiative. Studies in health technology and informatics 2014. link